File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Cross-reactive antibody response between SARS-CoV-2 and SARS-CoV infections

TitleCross-reactive antibody response between SARS-CoV-2 and SARS-CoV infections
Authors
Keywordsanimal experiment
animal model
animal tissue
antibody dependent enhancement
antigen binding
Issue Date2020
PublisherElsevier (Cell Press): OAJ. The Journal's web site is located at http://cell.com/cell-reports
Citation
Cell Reports, 2020, v. 31 n. 9, p. article no. 107725 How to Cite?
AbstractThe World Health Organization has declared the ongoing outbreak of COVID-19, which is caused by a novel coronavirus SARS-CoV-2, a pandemic. There is currently a lack of knowledge about the antibody response elicited from SARS-CoV-2 infection. One major immunological question concerns antigenic differences between SARS-CoV-2 and SARS-CoV. We address this question by analyzing plasma from patients infected by SARS-CoV-2 or SARS-CoV and from infected or immunized mice. Our results show that, although cross-reactivity in antibody binding to the spike protein is common, cross-neutralization of the live viruses may be rare, indicating the presence of a non-neutralizing antibody response to conserved epitopes in the spike. Whether such low or non-neutralizing antibody response leads to antibody-dependent disease enhancement needs to be addressed in the future. Overall, this study not only addresses a fundamental question regarding antigenicity differences between SARS-CoV-2 and SARS-CoV but also has implications for immunogen design and vaccine development.
Persistent Identifierhttp://hdl.handle.net/10722/289551
ISSN
2020 Impact Factor: 9.423
2020 SCImago Journal Rankings: 6.264
PubMed Central ID
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorLyu, H-
dc.contributor.authorWu, NC-
dc.contributor.authorTsang, OTY-
dc.contributor.authorYuan, M-
dc.contributor.authorPerera, RAPM-
dc.contributor.authorLeung, WS-
dc.contributor.authorSO, RTY-
dc.contributor.authorChan, JMC-
dc.contributor.authorYip, GK-
dc.contributor.authorChik, TSH-
dc.contributor.authorWang, Y-
dc.contributor.authorChoi, CYC-
dc.contributor.authorLin, Y-
dc.contributor.authorNg, WW-
dc.contributor.authorZhao, J-
dc.contributor.authorPoon, LLM-
dc.contributor.authorPeiris, JSM-
dc.contributor.authorWilson, IA-
dc.contributor.authorMok, CKP-
dc.date.accessioned2020-10-22T08:14:14Z-
dc.date.available2020-10-22T08:14:14Z-
dc.date.issued2020-
dc.identifier.citationCell Reports, 2020, v. 31 n. 9, p. article no. 107725-
dc.identifier.issn2211-1247-
dc.identifier.urihttp://hdl.handle.net/10722/289551-
dc.description.abstractThe World Health Organization has declared the ongoing outbreak of COVID-19, which is caused by a novel coronavirus SARS-CoV-2, a pandemic. There is currently a lack of knowledge about the antibody response elicited from SARS-CoV-2 infection. One major immunological question concerns antigenic differences between SARS-CoV-2 and SARS-CoV. We address this question by analyzing plasma from patients infected by SARS-CoV-2 or SARS-CoV and from infected or immunized mice. Our results show that, although cross-reactivity in antibody binding to the spike protein is common, cross-neutralization of the live viruses may be rare, indicating the presence of a non-neutralizing antibody response to conserved epitopes in the spike. Whether such low or non-neutralizing antibody response leads to antibody-dependent disease enhancement needs to be addressed in the future. Overall, this study not only addresses a fundamental question regarding antigenicity differences between SARS-CoV-2 and SARS-CoV but also has implications for immunogen design and vaccine development.-
dc.languageeng-
dc.publisherElsevier (Cell Press): OAJ. The Journal's web site is located at http://cell.com/cell-reports-
dc.relation.ispartofCell Reports-
dc.rightsThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.-
dc.subjectanimal experiment-
dc.subjectanimal model-
dc.subjectanimal tissue-
dc.subjectantibody dependent enhancement-
dc.subjectantigen binding-
dc.titleCross-reactive antibody response between SARS-CoV-2 and SARS-CoV infections-
dc.typeArticle-
dc.identifier.emailPerera, RAPM: mahenp@hku.hk-
dc.identifier.emailNg, WW: nwsprp@hku.hk-
dc.identifier.emailPoon, LLM: llmpoon@hkucc.hku.hk-
dc.identifier.emailPeiris, JSM: malik@hkucc.hku.hk-
dc.identifier.emailMok, CKP: ch02mkp@hkucc.hku.hk-
dc.identifier.authorityPerera, RAPM=rp02500-
dc.identifier.authorityPoon, LLM=rp00484-
dc.identifier.authorityPeiris, JSM=rp00410-
dc.identifier.authorityMok, CKP=rp01805-
dc.description.naturepublished_or_final_version-
dc.identifier.doi10.1016/j.celrep.2020.107725-
dc.identifier.pmid32426212-
dc.identifier.pmcidPMC7231734-
dc.identifier.scopuseid_2-s2.0-85085293514-
dc.identifier.hkuros317048-
dc.identifier.volume31-
dc.identifier.issue9-
dc.identifier.spagearticle no. 107725-
dc.identifier.epagearticle no. 107725-
dc.identifier.isiWOS:000538168300021-
dc.publisher.placeUnited States-
dc.identifier.issnl2211-1247-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats